Finnish drugmaker Orion says that its licensee, US health care major Abbott Laboratories, has decided not to continue the US development program for its intravenously administered drug Simdax (levosimendan), Orion's product for acute decompensated heart failure, because "it would not be commercially reasonable." Accordingly, the considered additional Phase III studies will not be conducted by Abbott, which continues to assess feedback on the agent from discussions with European authorities. Simdax will remain available in already-approved markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze